

Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Jan-2021
Document Type: USP Monographs
DocId: GUID-473D9F75-B39B-4B07-82CD-791261EBC13B_5_en-US
DOI: https://doi.org/10.31003/USPNF_M33170_05_01
DOI Ref: lop9c

© 2025 USPC
Do not distribute

Filgrastim

MTPLGPASSL PQSFLLKCLE QVRKIQGDGA ALQEKL^CATY KLCHPEELVL
LGHSLGIPWA PLSSCPSQAL QLAGCLSQLH SGLFLYQGLL QALEGISPEL
GPTLDTLQLD VADFATTIWIQ QMEELGMAPA LQPTQGAMPA FASAFQRRAAG
GVLVASHLQS FLEVSYRVLR HLAQP

$C_{845}H_{1339}N_{223}O_{243}S_9$ 18,799 daltons CAS RN®: 121181-53-1; UNII: PVI5M0M1GW.

DEFINITION

Filgrastim is a recombinant form of human granulocyte colony-stimulating factor (r-metHuG-CSF). It is a single chain, 175 amino acid nonglycosylated polypeptide produced by *Escherichia coli* bacteria transfected with a gene encoding a methionyl human granulocyte colony-stimulating factor. When prepared as a drug substance, it contains NLT 0.9 mg/mL of Filgrastim. Formulation contains one or more suitable buffering and/or stabilizing agents. The presence of host cell DNA and protein in Filgrastim is process-specific. The capability of the process to clear host-derived DNA and protein requires validation and is determined by validated methods. It has a biological potency of NLT 80% and NMT 125% relative to standard on a mass-to-mass basis.

IDENTIFICATION

- **A.** It meets the requirements in the Assay.
- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the test for *Organic Impurities, Related Compounds*.

Change to read:

• **C. PEPTIDE MAPPING**

(See [Biotechnology-Derived Articles—Peptide Mapping \(1055\)](#).)

Solution A: [Water](#) and [trifluoroacetic acid](#) (1000:1)

Solution B: Transfer 100 mL of [water](#) to a 1000-mL volumetric flask, add 1 mL of [trifluoroacetic acid](#), and dilute with [acetonitrile](#) to volume.

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	98	2
2	98	2
30	70	30
75	40	60
90	2	98
100	2	98
101	98	2
120	98	2

Tris buffer: Prepare a 0.5 M [tris\(hydroxymethyl\) aminomethane](#) solution, and adjust with [hydrochloric acid](#) to a pH of 8.1.

Methylamine solution: Dissolve 0.27 g of [methylamine hydrochloride](#) in 10 mL of [water](#).

DTT solution: 30.9 mg/mL of [dithiothreitol](#) in [water](#), freshly prepared

Digestion solution: Dissolve 0.30 g of [urea](#) in 200 μ L of *Tris buffer*, 100 μ L of *Methylamine solution*, 50 μ L of *DTT solution*, and 420 μ L of [water](#). Overlay with nitrogen, and use immediately.

Endoproteinase Glu-C solution: 0.2 μ g/ μ L of [endoproteinase Glu-C](#) in [water](#). Use immediately.

TFA solution: [Water](#) and [trifluoroacetic acid](#) (100:5)

Standard solution: Prepare a solution containing 80 µg of [▲USP Filgrastim System Suitability RS](#)▲ (IRA 1-Jan-2021) and 200 µL of *Digestion solution* in a suitable tube. Add [water](#) to a final volume of 390 µL. Add 10 µL of *Endoproteinase Glu-C solution*. Cap the tube, mix well, and incubate at approximately 25° for 18 h. Add 18 µL of *TFA solution*.▲ (IRA 1-Jan-2021)

Sample solution: ▲Prepare a solution containing 80 µg of filgrastim and 200 µL of *Digestion solution* in a suitable tube. Add [water](#) to a final volume of 390 µL. Add 10 µL of *Endoproteinase Glu-C solution*. Cap the tube, mix well, and incubate at approximately 25° for 18 h. Add 18 µL of *TFA solution*.▲ (IRA 1-Jan-2021)

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 214 nm

Column: 2.1-mm × 25-cm; packing [L26](#)

Column temperature: 40°

Flow rate: 0.2 mL/min

Injection volume: 70 µL

System suitability requirements: Eight major peaks should be present in each chromatogram as illustrated in the reference chromatogram provided with [▲USP Filgrastim System Suitability RS](#).▲ (IRA 1-Jan-2021) The absolute difference in retention time of each of the eight major peaks between the two *Standard solution* chromatograms must be ≤0.5 min. The difference in retention time of each of the eight major peaks between the *Sample solution* chromatogram and the average of the *Standard solution* chromatograms must be ≤0.5 min. The relative difference in peak height of each of the eight major peaks between the two *Standard solution* chromatograms must be ≤15%.

Analysis

Samples: *Standard solution* and *Sample solution*

[*NOTE*—Condition the *Chromatographic system* by running at least two blank gradient programs before injecting the digests. Separately inject the *Standard solution*, *Sample solution*, and *Standard solution* again, and record the responses of each peak.]

Acceptance criteria: The chromatographic profile of the *Sample solution* is similar to that of the *Standard solution*. The relative difference in peak height between the normalized sample peak height (normalized by total peak height versus the average total peak height of the *Standard solution* chromatograms) and the average standard peak height of each of the eight major peaks must be ≤15%.

ASSAY

Change to read:

• POTENCY

Medium A: [RPMI 1640](#) modified to contain 2 mM [L-glutamine](#), 2 g/L of [sodium bicarbonate](#), 4.5 g/L of [glucose](#), 10 mM [▲N-\(2-Hydroxyethyl\)piperazine-N'-\(ethanesulfonic acid\)](#)▲ (IRA 1-Jan-2021) [HEPES], 1 mM [sodium pyruvate](#), 0.05 mM [2-mercaptoethanol](#), and 5% heat-inactivated fetal bovine serum (FBS). The [2-mercaptoethanol](#) is prepared fresh and added immediately before use.

Medium B: [RPMI 1640](#) modified to contain 2 mM [L-glutamine](#), 2 g/L of [sodium bicarbonate](#), 4.5 g/L of [glucose](#), 10 mM HEPES, 1 mM [sodium pyruvate](#), 0.05 mM [2-mercaptoethanol](#), and 1% heat-inactivated FBS. The [2-mercaptoethanol](#) is prepared fresh and added immediately before use.

Medium C: Prepare a mixture of *Medium A* with 20 ng/mL of [interleukin 3](#) (IL-3).

Medium D: Prepare a mixture of *Medium A* with 1 ng/mL of [granulocyte colony-stimulating factor](#) (G-CSF).

Substrate solution: Reconstitute the luminescence substrate² with the supplied buffer. Aliquot the solution and store below –65° for up to 2 months.

Standard solution: 0.5 ng/mL of [▲USP Filgrastim for Bioassay RS](#)▲ (IRA 1-Jan-2021) in *Medium B*. [*NOTE*—Do not use single step dilutions of more than 1:100 and smaller transfer volumes than 40 µL while performing serial dilutions. Mix gently and thoroughly (do not vortex).]

Positive control solution: 10 ng/mL of [▲USP Filgrastim for Bioassay RS](#)▲ (IRA 1-Jan-2021) in *Medium B*

Sample solution: 0.5 ng/mL of Filgrastim in *Medium B*. [*NOTE*—Do not use single step dilutions of more than 1:100 and smaller transfer volumes than 40 µL while performing serial dilutions. Mix gently and thoroughly (do not vortex).]

Cell culture preparation: Adapt [M-NFS-60 cells](#)³ to growth in [G-CSF](#). Culture the cells at 5% carbon dioxide (CO₂) and 37°. Cells should be passaged two times per week and reseeded at a density of 3 × 10⁴ cells/mL for 3 days or 1 × 10⁴ cells/mL for 4 days. Passage the cultures in *Medium C* until passage two. Transfer the cells into *Medium D*, and passage the cultures until passage 11. After passage 11, the cells are defined as [G-CSF](#) adapted and can be used in the Assay or can be banked. Bank the cells at a density of approximately 1.5 × 10⁶ cells/mL in banking medium [90% FBS, 10% [dimethyl sulfoxide](#) (DMSO)]. Upon thawing the banked cells, culture the cells for 2–3 passages in *Medium D* before using in the Assay.

Cell suspension: Wash the cells twice with [phosphate buffered saline](#) (PBS), and adjust the cell concentration to 1 × 10⁵ cells/mL in *Medium B*.

Preparation of cells for analysis: Use a 96-well flat-bottomed black microtiter plate (optically clear well bottoms) with wells arranged in eight rows (labeled A through H) with 12 wells (numbered 1 to 12) in each row. Place 50 µL of *Cell suspension* into all wells of the 96-well microtiter plate except the wells of column 1 (A1–H1, blank). Column 1 is filled with 50 µL of *Medium B*. Incubate the plate at 37° in the incubator until the *Standard solution* and the *Sample solution* are ready, for a maximum of 1 h.

Preparation of diluted Standard solution and Sample solution: Use a 96-well round-bottom microtiter plate with wells arranged in eight rows (labeled A through H) with 12 wells (numbered 1 to 12) in each row. Dispense 100 μ L of *Medium B* into each well of the plate except column 12 (wells A12–H12, positive control) and A2–A10. Pipet 200 μ L of *Standard solution* into wells A3, A6, and A9; and 200 μ L of *Sample solution* into wells A2, A5, and A8. Two samples can be prepared on one plate. The second sample can be added to wells A4, A7, and A10. Pipet 100 μ L of *Positive control solution* into all wells of the last column (A12–H12). Using a multi-channel pipet (12 channels), perform two-fold dilutions on the plate. Aspirate 100 μ L from the first row (A2–A10), transfer to the second row, and mix three times. Then aspirate 100 μ L from the second row, transfer to the third row, and mix three times. Repeat this procedure across the entire plate until row H. Discard the 100 μ L aspirated from the last row.

System suitability requirements: The signal-to-noise ratio between the mean chemiluminescence signal of the positive control and the mean chemiluminescence signal of the negative control (A11–H11) should be ≥ 3 . The number of technical outliers may not exceed four per curve.

Analysis: Using a multi-channel pipet, transfer 50 μ L from each well of the round-bottom microtiter plate (containing the *Standard solution* and *Sample solution* serial dilutions, blanks, and positive and negative controls) into the same well of the black microtiter plate containing the cell suspension starting with the lowest concentration. Mix three times. Incubate the black microtiter plate in a humidified CO_2 incubator for 31 ± 2 h at 37° with 5% CO_2 . Add 100 μ L of reconstituted *Substrate solution* to all wells. Incubate the plate for 15 min at room temperature while gently agitating the plate on a plate shaker. Incubate the plate for an additional 15 min at room temperature without shaking. Read the plate in a microtiter plate luminescence reader.

Calculations: For each sample, first calculate the relative potency of Filgrastim (in percent) using statistical methods for parallel-line assays, then calculate potency in IU/mL. The statistical tests for linearity, slope, and parallelism for each sample compared to the standard have to be passed at the 95% level. The confidence limit must be within 75% and 133% of the estimated potency.

Acceptance criteria: The mean estimated potency is NLT 80% and NMT 125% of the stated potency.

IMPURITIES

Change to read:

• **ORGANIC IMPURITIES, RELATED COMPOUNDS**

Solution A: [Water](#) and [trifluoroacetic acid](#) (1000:1)

Solution B: Transfer 100 mL of [water](#) to a 1000-mL volumetric flask, add 1 mL of [trifluoroacetic acid](#), and dilute with [acetonitrile](#) to volume.

Mobile phase: See [Table 2](#).

Table 2

Time (min)	Solution A (%)	Solution B (%)
0	60	40
30	20	80
35	20	80
45	60	40
55	60	40

Standard solution: 0.75 mg/mL of ▲[USP Filgrastim System Suitability RS](#)▲ (IRA 1-Jan-2021) in [water](#)

Sample solution: 0.75 mg/mL of Filgrastim in [water](#)

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm \times 15-cm; packing [L26](#)

Column temperature: 60°

Flow rate: 0.8 mL/min

Injection volume: 33 μ L

System suitability

Sample: *Standard solution*

Suitability requirements

Relative retention times: About 0.91 for oxidized Filgrastim 1, about 0.98 for oxidized Filgrastim 2, and about 1.04 for reduced Filgrastim relative to the major peak

Relative standard deviation: The relative standard deviation of the total area (main peak and minor product related peaks, excluding the void peak) and the relative standard deviation of the retention time of the major Filgrastim peak for replicate injections is NMT 5%.

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of oxidized Filgrastim 1, oxidized Filgrastim 2, Filgrastim, and reduced Filgrastim in the portion of Filgrastim taken:

$$\text{Result} = (r_u/r_T) \times 100$$

r_u = peak response for each impurity

r_T = sum of the responses of all the peaks

Acceptance criteria

Individual impurities: NMT 1.0% of reduced Filgrastim

Total impurities: NMT 2.0%

Change to read:

- **IMPURITIES WITH CHARGES DIFFERENT FROM FILGRASTIM**

(See [Biotechnology-Derived Articles—Isoelectric Focusing \(1054\)](#).)

1 M phosphoric acid solution: Dilute 6.8 mL of 85% [phosphoric acid](#) with [water](#) to a final volume of 100 mL.

1 M sodium hydroxide solution: Dilute 10 mL of 10 M [sodium hydroxide](#) with [water](#) to a final volume of 100 mL.

Anolyte solution: Add 10 mL of **1 M phosphoric acid solution** to 90 mL of [water](#) to obtain a 0.1 M [phosphoric acid](#) solution.

Catholyte solution: Add 10 mL of **1 M sodium hydroxide solution** to 90 mL of [water](#) to obtain a 0.1 M [sodium hydroxide](#) solution.

Initiator: Measure 0.072 g of [potassium persulfate](#) to 10 mL of [water](#) to obtain a 0.72% [potassium persulfate](#) solution.

Fixing solution: Mix 35 g of [sulfosalicylic acid](#) and 100 g of [trichloroacetic acid](#) in 1000 mL of [water](#).

Gel wash: Prepare a solution containing, in each liter, 400 mL of absolute [methanol](#), 100 mL of [glacial acetic acid](#), and [water](#).

Coomassie staining solution: Measure 1.25 g of [Coomassie Brilliant Blue R-250](#) into 1 L of **Gel wash**.

Coomassie destaining solution: Prepare a solution containing, in each liter, 75 mL of absolute [methanol](#), 100 mL of [glacial acetic acid](#), and [water](#).

Reference solution A: 1 mg/mL of ▲[USP Filgrastim System Suitability RS](#) ▲ (IRA 1-Jan-2021) in [water](#)

Reference solution B: Dilute **Reference solution A** with [water](#) to obtain a concentration of 20 µg/mL of ▲[USP Filgrastim System Suitability RS](#) ▲ (IRA 1-Jan-2021)

Reference solution C: 3 mg/mL of ▲[USP Filgrastim System Suitability RS](#) ▲ (IRA 1-Jan-2021) in [water](#)

Reference solution D: Use an isoelectric point (pl) calibration solution, in the pl range of 2.5–6.5, prepared according to the manufacturer's instructions.

Sample solution: 1 mg/mL of Filgrastim in [water](#)

Gel: Prepare a 6% T (total [acrylamide](#)), 0.16% C ([bisacrylamide](#)) gel containing 0.3 g/mL of [urea](#), 1.5% pH 3–10 [ampholytes](#), 3.7% pH 5–7 [ampholytes](#), and 0.05% *Initiator*.

System suitability requirements: The isoelectric point markers are distributed along the entire length of the gel; no artifacts obscure visualization of the bands; and **Reference solution B** must be visible.

Analysis: Gel electrophoresis is carried out on a horizontal gel apparatus at 10° and a constant power setting of 10 W (voltage and current are allowed to vary). Pre-focus the gel for 20–40 min. Apply 10 µL of **Sample solution** (10 µg), **Reference solution A** (10 µg), **Reference solution B** (0.2 µg), and **Reference solution C** (30 µg) to separate lanes on the gel. Apply about 10 µL of **Reference solution D** to each side of the gel. Focus the gel for about 2.5 h at 10° at a constant power setting of 10 W (voltage and current are allowed to vary). Remove the gel from the apparatus, place in a sufficient volume of **Fixing solution** to submerge the gel, and rock gently for NLT 15 min. Decant, and repeat wash in **Fixing solution** for an additional 15 min. Remove the **Fixing solution**, and submerge the gel in **Gel Wash** with gentle mixing for NLT 30 min. Decant the **Gel Wash** solution, and immerse the gel in **Coomassie staining solution** with gentle mixing for 15–60 min. Remove the **Coomassie staining solution**, rinse the gel with **Coomassie destaining solution**, and submerge the gel in fresh **Coomassie destaining solution**. Continue rocking the gel in **Coomassie destaining solution** until the background is clear and **Reference solution B** is still visible. Visually examine the gel.

Acceptance criteria: The major band in the **Sample solution** focuses at the same position as the major band in **Reference solution A**. Minor bands present in the **Sample solution** are also observed in **Reference solution C** and, based on visual estimates, are less intense or equal to **Reference solution B**. There are no bands observed in the **Sample solution** that are not present in **Reference solution C**.

Change to read:

- **IMPURITIES WITH MOLECULAR WEIGHT DIFFERENT FROM THAT OF FILGRASTIM**

(See [Biotechnology-Derived Articles—Polyacrylamide Gel Electrophoresis \(1056\)](#).)

4X SDS sample buffer (nonreducing conditions): Prepare a solution containing, in each milliliter, 80 mg of [sodium dodecyl sulfate](#) and 30 mg of [tris\(hydroxymethyl\)aminomethane](#). Adjust with [hydrochloric acid](#) to a pH of 6.8. Add 0.80 mg/mL of [bromophenol blue](#) and 0.4 mL/mL of [glycerol](#).

4X SDS sample buffer (reducing conditions): Prepare a solution containing, in each milliliter, 80 mg of [sodium dodecyl sulfate](#), 30 mg of [tris\(hydroxymethyl\)aminomethane](#), and 38.5 mg of [dithiothreitol](#). Adjust with [hydrochloric acid](#) to a pH of 6.8. Add 0.80 mg/mL of [bromophenol blue](#) and 0.4 mL/mL of [glycerol](#).

1X SDS sample buffer (nonreducing conditions): Dilute 1 volume of the **4X SDS sample buffer (nonreducing conditions)** with 3 volumes of [water](#).

1X SDS sample buffer (reducing conditions): Dilute 1 volume of the 4X SDS sample buffer (reducing conditions) with 3 volumes of [water](#).

Gel wash I: Prepare a solution containing, in each liter, 400 mL of absolute [methanol](#), 100 mL of [glacial acetic acid](#), and [water](#).

Gel wash II: Prepare a solution containing, in each liter, 100 mL of 95% [ethanol](#), 50 mL of [glacial acetic acid](#), and [water](#).

Reducer solution: Prepare a solution containing 2 mg of [dithiothreitol](#) in 400 mL of [water](#). [NOTE—Prepare this solution immediately before use, and protect it from light. This amount of solution is sufficient for two slab gels.]

Silver nitrate solution: Measure 0.68 g of [silver nitrate](#) in 400 mL of water, and mix well. [NOTE—Prepare this solution immediately before use, and protect it from light. This amount of solution is sufficient for two slab gels.]

Developer: To 500 mL of water add 18.6 g of [sodium carbonate monohydrate](#) and 0.5 mL of [formaldehyde](#). [NOTE—Prepare this solution fresh at the time of use. This amount of solution is sufficient for two slab gels.]

Acetic acid solution: Prepare a solution containing, in each liter, 50 mL of [glacial acetic acid](#) and [water](#).

Running buffer: Prepare a buffer solution containing 1 g of [sodium dodecyl sulfate](#), 3.03 g of [tris\(hydroxymethyl\)aminomethane](#), and 14.4 g of [glycine](#) per liter.

Resolving gel: Use a 1.5-mm thick, 10%–20% [polyacrylamide](#) gradient gel [10%–20% T, 2.6% C ([bisacrylamide](#))].

Stacking gel: 4% T (total [acrylamide](#)), 2.6% C ([bisacrylamide](#))

Reference solution A: Dilute 25 µg of [USP Filgrastim System Suitability RS](#)▲ (IRA 1-Jan-2021) with 25 µL of the appropriate 4X SDS sample buffer and sufficient water to obtain 100 µL of a solution containing ▲250 µg/mL of [USP Filgrastim System Suitability RS](#)▲ (IRA 1-Jan-2021) in 1X SDS sample buffer. Prepare both a reduced and a nonreduced *Reference solution A* using the appropriate 4X SDS sample buffer. Heat reduced sample at approximately 65° for 5–10 min. Do not heat the nonreduced sample.

Reference solution B: Prepare both a reduced and a nonreduced *Reference solution B* by diluting *Reference solution A* (1:100) with the appropriate 1X SDS sample buffer to obtain a 2.5-µg/mL preparation of [USP Filgrastim System Suitability RS](#)▲ (IRA 1-Jan-2021). Heat reduced sample at approximately 65° for 5–10 min. Do not heat the nonreduced sample.

Reference solution C: Dilute 75 µg of [USP Filgrastim System Suitability RS](#)▲ (IRA 1-Jan-2021) with 25 µL of the appropriate 4X SDS sample buffer and sufficient [water](#) to obtain 100 µL of a solution containing ▲750 µg/mL of [USP Filgrastim System Suitability RS](#)▲ (IRA 1-Jan-2021) in 1X SDS sample buffer. Prepare both a reduced and a nonreduced *Reference solution C* using the appropriate 4X SDS sample buffer. Heat reduced sample at approximately 65° for 5–10 min. Do not heat the nonreduced sample.

Reference solution D: Use a solution of molecular weight markers suitable for calibrating SDS-polyacrylamide gels in the range of 14.4–94 kDa.

Sample solution: Dilute 25 µg of the sample to be tested with 25 µL of the appropriate 4X SDS sample buffer and sufficient [water](#) to obtain 100 µL of a solution containing a 250-µg/mL preparation of the test article in 1X SDS sample buffer. Prepare both a reduced and a nonreduced *Sample solution* using the appropriate 4X SDS sample buffer. Heat reduced sample at approximately 65° for 5–10 min. Do not heat the nonreduced sample.

Analysis: Separately apply 20 µL of the *Sample solution*, *Reference solution A*, *Reference solution B*, and *Reference solution C* into separate lanes of the gel. Apply about 20 µL of *Reference solution D* to each side of the gel. [NOTE—Reduced and nonreduced samples should either be run on separate gels or on the same gel if separated by at least three lanes containing 1X SDS sample buffer (nonreducing).] Perform the electrophoresis using a constant voltage of 125 V. [NOTE—Current and power are allowed to vary throughout the run.] Remove the gel from the apparatus after the tracking dye begins to approach the anode end of the gel, place the gel in a sufficient volume of *Gel Wash I* to submerge the gel, and mix gently for NLT 1 h. Decant the *Gel Wash I*, and immerse the gel in a similar volume of *Gel Wash II*. After 15 min of gentle mixing, decant, and wash the gel for an additional 15 min in *Gel Wash II*. Wash the gel twice for 15 min each with the *Reducer solution* followed by two washes of 15 min each in the *Silver nitrate solution*. Rinse twice with [water](#), and decant. Transfer the gel to a clear container containing a sufficient volume of the *Developer* to immerse the gel, and rock the container changing the *Developer* frequently (10–15 s) until the molecular weight markers and *Reference standard B* become visible. When the gel is visibly stained, wash immediately with the *Acetic acid solution*. Rinse the gel repeatedly with *Acetic acid solution* to remove the *Developer*, then rock gently for approximately 30 min. Visually examine the gel.

System suitability requirements: No artifacts obscure visualization of the bands, and *Reference solution B* must be visible.

Acceptance criteria: The main band in the *Sample solution* migrates to the same position as the main band in *Reference solution A*. Minor bands present in the *Sample solution* are also observed in *Reference solution C* and, based on visual estimates, are less intense or equal to *Reference solution B*. There are no bands observed in the *Sample solution* that are not present in *Reference solution C*.

Change to read:

• **LIMIT OF HIGH MOLECULAR WEIGHT PROTEINS**

Mobile phase: Add 11.5 g of concentrated [phosphoric acid](#) to 800 mL of water. Adjust with 10 N [sodium hydroxide](#) to a pH of 2.5, and dilute with water to 1000 mL. Filter, and degas.

Column conditioning solution: Dissolve 18 mg of bovine serum albumin (BSA) in 9 mL of [water](#).

Resolution solution: ▲0.3 mg/mL of [USP High Molecular Weight Filgrastim RS](#)▲ (IRA 1-Jan-2021)

Standard solution: 0.3 mg/mL of [USP Filgrastim System Suitability RS](#)▲ (IRA 1-Jan-2021) in [water](#)

Sample solution: Dilute Filgrastim with [water](#) to 0.3 mg/mL.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 214 nm**Column:** 7.8-mm × 30-cm; packing [L59](#)**Column temperature:** Ambient**Flow rate:** 1 mL/min**Injection volume:** 40 μ L**System suitability****Samples:** Column conditioning solution, Resolution solution, and Standard solution**Suitability requirements****Column solution peak response:** Chromatograph the Column conditioning solution 3–10 times. The peak response of the final consecutive injections should be constant.**Relative retention times:** Chromatograph the Resolution solution two times, and record the peak responses. The relative retention times are about 0.5 for Filgrastim aggregate, 0.9 for Filgrastim dimer, and 1.0 for Filgrastim monomer.**Relative standard deviation:** The relative standard deviation of the total area (main peak and minor product related peaks, excluding the void peak) for replicate injections of the Standard solution is NMT 3%. The relative standard deviation of the retention time of the major Filgrastim peak for replicate injections of the Standard solution is NMT 3%.**Analysis****Samples:** Standard solution and Sample solution

Measure the areas of the main peak and of the peaks eluting prior to the main peak, excluding the solvent peaks. Calculate the percentage of aggregates (peaks eluting before dimer), dimer, and monomer in the portion of Filgrastim taken:

$$\text{Result} = (r_u/r_T) \times 100$$

 r_u = individual peak response of aggregates, dimer, and monomer r_T = sum of the responses of all the peaks**Acceptance criteria****Individual impurities:** NMT 0.5% of aggregate**Total high molecular weight impurities:** NMT 2.0%**SPECIFIC TESTS****Change to read:****• PROTEIN CONCENTRATION**(See [Biotechnology-Derived Articles—Total Protein Assay \(1057\)](#).)**5% Sorbitol solution, pH 3.25:** Prepare a 5% solution of [sorbitol](#) in [water](#), and adjust with [hydrochloric acid](#) to a pH of 3.25.**Sample solution:** Dilute the Filgrastim in 5% Sorbitol solution, pH 3.25 to obtain a solution with a concentration between 0.2 and 1.7 mg/mL.**Blank:** 5% Sorbitol solution, pH 3.25**Instrumental conditions****Mode:** UV-Vis**Analytical wavelengths:** 280, 320, and 350 nm**Cell:** Quartz spectrophotometric cell of path length 1 cm**Analysis****Sample:** Sample solution

Calculate the sample absorbance at 320 nm as a percentage of the absorbance at 280 nm:

$$\text{Result} = (A_{320}/A_{280}) \times 100$$

 A_{320} = absorbance value of the Sample solution at 320 nm A_{280} = absorbance value of the Sample solution at 280 nm

If the absorbance at 320 nm is less than 5.0% of the absorbance at 280 nm, calculate the protein concentration of the Filgrastim sample:

$$\text{Result} = A_{280} \times D^{\Delta} (IRA 1-Jan-2021) / 0.86$$

 A_{280} = absorbance value of the Sample solution at 280 nm $D^{\Delta} (IRA 1-Jan-2021)$ = dilution factor of the Sample solution

If the absorbance at 320 nm is more than 5.0% of the absorbance at 280 nm, calculate the protein concentration of the Filgrastim sample:

$$\text{Result} = \{A_{280} - [(3.3435 \times A_{320}) - (2.3435 \times A_{350})]\} \times D^{\Delta} (IRA 1-Jan-2021) / 0.86$$

A_{280} = absorbance value of the *Sample solution* at 280 nm A_{320} = absorbance value of the *Sample solution* at 320 nm A_{350} = absorbance value of the *Sample solution* at 350 nm D_{Δ} (IRA 1-Jan-2021)= dilution factor of the *Sample solution*

- **MICROBIAL ENUMERATION TESTS (61)** and **TESTS FOR SPECIFIED MICROORGANISMS (62)**: The total aerobic count does not exceed 0 cfu/10 mL of the substance solution.

- **BACTERIAL ENDOTOXINS TEST (85)**: It contains NMT 2 USP Endotoxin Units/mg of drug substance.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE**: Preserve in tight containers. Store between 2° and 8°. Protect from light during long-term storage.
- **LABELING**: Label to indicate the content of the drug substance in grams per container. The labeling states that the material is of recombinant DNA origin.

Change to read:

- **USP REFERENCE STANDARDS (11)**

▲ [USP Filgrastim for Bioassay RS](#)

[USP Filgrastim System Suitability RS](#)

[USP High Molecular Weight Filgrastim RS](#) ▲ (IRA 1-Jan-2021)

¹ A suitable RPMI 1640 medium is available from ATCC (catalog no.: 30-2001), or use an equivalent formulation.

² A suitable substrate is available from Promega (Cell Titer Glo-Luminescence Kit, catalog no.: G7572) or equivalent.

³ M-NFS-60 cells can be obtained from ATCC (catalog no.: CRL-1838) or suitable equivalent.

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
FILGRASTIM	Rebecca C. Potts Associate Scientific Liaison	BIO2 Biologics Monographs 2 - Proteins

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 46(4)

Current DocID: GUID-473D9F75-B39B-4B07-82CD-791261EBC13B_5_en-US

DOI: https://doi.org/10.31003/USPNF_M33170_05_01

DOI ref: [lop9c](#)